Advertisement

Kleinwuchs

  • Uwe Martin Maus
  • Thomas Vetter
  • J. Oliver Semler
  • Christine Hofmann
  • Klaus M. Peters
  • Andreas Roth
  • André Sachse
Part of the Fortbildung Osteologie book series (FORTOSTEO, volume 4)

Zusammenfassung

Zunächst werden die Formen und Ursachen des Kleinwuchses vorgestellt. Unter anderem wird detailliert eingegangen auf die Osteogenesis imperfecta (OI), die Hypophosphatasie, die Hypophosphatämie und die Achondroplasie sowie die chirurgisch-orthopädischen Versorgungsmöglichkeiten der unteren Extremitäten kleinwüchsiger Menschen. Unter dem Namen Contergan wurde die Substanz Thalidomid am 01.10.1957 in Deutschland als rezeptfreies Schlaf- und Beruhigungsmittel zugelassen. Anders als bei den bis zu diesem Zeitpunkt verfügbaren Schlafmitteln, den Barbituraten, führte eine Überdosierung mit Thalidomid nicht zum Fruchttod. Katastrophale Folgen hatte die Einnahme in der Schwangerschaft gleichwohl.

Literatur

Literatur zu Abschn. 6.1

  1. Ahmed ML, Allen AD, Sharma A, Macfarlane JA, Dunger DB (1993) Evaluation of a district growth screening programme: the Oxford Growth Study. Arch Dis Child 69 (3): 361–365CrossRefPubMedCentralGoogle Scholar
  2. Andersen PE Jr, Hauge M (1989) Congenital generalised bone dysplasias: a clinical, radiological, and epidemiological survey. J Med Genet 26 (1): 37–44CrossRefPubMedCentralGoogle Scholar
  3. Barbosa-Buck CO, Orioli IM, da Graca Dutra M, Lopez-Camelo J, Castilla EE, Cavalcanti DP (2012) Clinical epidemiology of skeletal dysplasias in South America. Am J Med Genet A 158A (5): 1038–1045. doi: 10.1002/ajmg.a.35246CrossRefPubMedCentralGoogle Scholar
  4. Baxter L, Bryant J, Cave CB, Milne R (2007) Recombinant growth hormone for children and adolescents with Turner syndrome. Cochrane Database Syst Rev (1): CD003887. doi: 10.1002/14651858.CD003887.pub2
  5. Bernstein PS, Divon MY (1997) Etiologies of fetal growth restriction. Clin Obstet Gynecol 40 (4): 723–729CrossRefPubMedCentralGoogle Scholar
  6. Binder G (2011) Short stature due to SHOX deficiency: genotype, phenotype, and therapy. Horm Res Paediatr 75 (2): 81–89. doi: 10.1159/000324105000324105 [pii]
  7. Binder G, Woelfe J (2010) AWMF S1-Leitlinie Kleinwuchs. AWMF Register Nr. 174/004 http://www.awmf.org/uploads/tx_szleitlinien/174–004l_S1_Kleinwuchs_ 2017–03.pdf
  8. Franco B, Laura F, Sara N, Salvatore G (2013) Thyroid function in small for gestational age newborns: a review. J Clin Res Pediatr Endocrinol 5 Suppl 1: 2–7. doi: 10.4274/jcrpe.846
  9. Hwang IT (2014) Efficacy and safety of growth hormone treatment for children born small for gestational age. Korean J Pediatr 57 (9): 379–383. doi: 10.3345/kjp.2014.57.9.379CrossRefPubMedCentralGoogle Scholar
  10. Keller C, Keller KR, Shew SB, Plon SE (1999) Growth deficiency and malnutrition in Bloom syndrome. J Pediatr 134 (4): 472–479. doi: S0022–3476 (99)70206–4 [pii]Google Scholar
  11. Khadilkar VV, Frazer FL, Skuse DH, Stanhope R (1998) Metaphyseal growth arrest lines in psychosocial short stature. Arch Dis Child 79 (3): 260–262CrossRefPubMedCentralGoogle Scholar
  12. Kramer MS (1987) Determinants of low birth weight: methodological assessment and meta-analysis. Bull World Health Organ 65 (5): 663–737Google Scholar
  13. Lewy JE, New MI (1975) Growth in children with renal failure. Am J Med 58 (1): 65–68CrossRefPubMedCentralGoogle Scholar
  14. Lifshitz F (2009) Nutrition and growth. J Clin Res Pediatr Endocrinol 1 (4): 157–163. doi: 10.4008/jcrpe.v1i4.39
  15. Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M (1994) Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr 125 (1): 29–35. doi: S0022–3476 (94)70117–2 [pii]Google Scholar
  16. Lubchenco LO, Hansman C, Boyd E (1966) Intrauterine growth in length and head circumference as estimated from live births at gestational ages from 26 to 42 weeks. Pediatrics 37 (3): 403–408Google Scholar
  17. Lubchenco LO, Hansman C, Dressler M, Boyd E (1963) Intrauterine Growth as Estimated from Liveborn Birth-Weight Data at 24 to 42 Weeks of Gestation. Pediatrics 32: 793–800Google Scholar
  18. Marshall WA, Tanner JM (1968) Growth and physiological development during adolescence. Annu Rev Med 19: 283–300. doi: 10.1146/annurev.me.19.020168.001435CrossRefPubMedCentralGoogle Scholar
  19. Marshall WA, Tanner JM (1969) Variations in pattern of pubertal changes in girls. Arch Dis Child 44 (235): 291–303CrossRefPubMedCentralGoogle Scholar
  20. Marshall WA, Tanner JM (1970) Variations in the pattern of pubertal changes in boys. Arch Dis Child 45 (239): 13–23CrossRefPubMedCentralGoogle Scholar
  21. Orioli IM, Castilla EE, Barbosa-Neto JG (1986) The birth prevalence rates for the skeletal dysplasias. J Med Genet 23 (4): 328–332CrossRefPubMedCentralGoogle Scholar
  22. Palmert MR, Dunkel L (2012) Clinical practice. Delayed puberty. N Engl J Med 366 (5): 443–453. doi: 10.1056/NEJMcp1109290CrossRefPubMedCentralGoogle Scholar
  23. Pedicelli S, Peschiaroli E, Violi E, Cianfarani S (2009) Controversies in the definition and treatment of idiopathic short stature (ISS). J Clin Res Pediatr Endocrinol 1 (3): 105–115. doi: 10.4008/jcrpe.v1i3.53CrossRefGoogle Scholar
  24. Ranke MB (1996) Towards a consensus on the definition of idiopathic short stature. Horm Res 45 Suppl 2: 64–66CrossRefPubMedCentralGoogle Scholar
  25. Rasmussen SA, Bieber FR, Benacerraf BR, Lachman RS, Rimoin DL, Holmes LB (1996) Epidemiology of osteochondrodysplasias: changing trends due to advances in prenatal diagnosis. Am J Med Genet 61 (1): 49–58. doi: 10.1002/(SICI)1096–8628 (19960102)61: 1<49: AID-AJMG10>3.0.CO;2-W [pii]
  26. Rikken B, Wit JM (1992) Prepubertal height velocity references over a wide age range. Arch Dis Child 67 (10): 1277–1280CrossRefPubMedCentralGoogle Scholar
  27. Sedlmeyer IL, Palmert MR (2002) Delayed puberty: analysis of a large case series from an academic center. J Clin Endocrinol Metab 87 (4): 1613–1620. doi: 10.1210/jcem.87.4.8395CrossRefGoogle Scholar
  28. Voss LD, Mulligan J, Betts PR, Wilkin TJ (1992) Poor growth in school entrants as an index of organic disease: the Wessex growth study. BMJ 305 (6866): 1400–1402CrossRefPubMedCentralGoogle Scholar
  29. Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, Mortier G, Mundlos S, Nishimura G, Rimoin DL, Robertson S, Savarirayan R, Sillence D, Spranger J, Unger S, Zabel B, Superti-Furga A (2011) Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A 155A (5): 943–968. doi: 10.1002/ajmg.a.33909CrossRefGoogle Scholar
  30. Wehkalampi K, Vangonen K, Laine T, Dunkel L (2007) Progressive reduction of relative height in childhood predicts adult stature below target height in boys with constitutional delay of growth and puberty. Horm Res 68 (2): 99–104. doi: 000101011 [pii]Google Scholar
  31. Wehkalampi K, Widen E, Laine T, Palotie A, Dunkel L (2008) Patterns of inheritance of constitutional delay of growth and puberty in families of adolescent girls and boys referred to specialist pediatric care. J Clin Endocrinol Metab 93 (3): 723–728. doi: jc.2007–1786 [pii]Google Scholar
  32. Wollmann HA (1998) Intrauterine growth restriction: definition and etiology. Horm Res 49 (Suppl 2): 1–6. doi: hre9b001 [pii]Google Scholar

Literatur zu Abschn. 6.2

  1. Barros ERG, Saraiva GL et al. (2012) Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 25 (5–6): 485–91Google Scholar
  2. Bianchi ML, Leonard MB et al.; International Society for Clinical (2014). Bone health in children and adolescents with chronic diseases that may affect the skeleton: the 2013 ISCD Pediatric Official Positions. J Clin Densitom 17 (2): 281–294Google Scholar
  3. Gatti D, Antoniazzi F et al. (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20 (5): 758–63CrossRefPubMedCentralGoogle Scholar
  4. Hoyer-Kuhn H, Semler O et al. (2014a) Effect of denosumab on the growing skeleton in osteogenesis imperfecta. J Clin Endocrinol Metab 99 (11): 3954–5CrossRefGoogle Scholar
  5. Hoyer-Kuhn H, Semler O et al. (2014b) A specialized rehabilitation approach improves mobility in children with osteogenesis imperfecta. J Musculoskelet Neuronal Interact 14 (4): 445–53Google Scholar
  6. Marini JC, Blissett AR (2013) New genes in bone development: What’s new in Osteogenesis imperfecta? J Clin Endocrinol Metab 8 (8): 3095–30103. doi: 10.1210/jc.2013-1505CrossRefGoogle Scholar
  7. Marini JC, Forlino A et al (2017). Osteogenesis imperfecta. Nat Rev Dis Primers 3: 17052CrossRefPubMedCentralGoogle Scholar
  8. Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363 (9418): 1377–85CrossRefGoogle Scholar
  9. Semler O, Hoyer-Kuhn H et al. (2012) Osteogenesis imperfecta. Medizinische Genetik 4: 297–309CrossRefGoogle Scholar
  10. Wirth T (2012) Osteogenesis imperfecta. Orthopäde 41 (9): 773–82; quiz 83–4CrossRefPubMedCentralGoogle Scholar

Literatur zu Abschn. 6.3

  1. Baumgartner-Sigl S, Haberlandt E, Mumm S, Scholl-Burgi S, Sergi C, Ryan L, Ericson KL, Whyte MP, Hogler W (2007) Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene. Bone 40 (6): 1655–1661. doi: S8756–3282(07)00052-X [pii]Google Scholar
  2. Beck C, Morbach H, Richl P, Stenzel M, Girschick HJ (2009a) How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases? Rheumatol Int 29 (3): 229–238CrossRefPubMedCentralGoogle Scholar
  3. Beck C, Morbach H, Stenzel M, Schneider P, Collmann H, Girschick G, Girschick HJ (2009b) [Hypophosphatasia]. Klin Padiatr 221 (4): 219–226CrossRefPubMedCentralGoogle Scholar
  4. Girschick HJ, Schneider P, Haubitz I, Hiort O, Collmann H, Beer M, Shin YS, Seyberth HW (2006) Effective NSAID treatment indicates that hyperprostaglandinism is affecting the clinical severity of childhood hypophosphatasia. Orphanet journal of rare diseases 1: 24. doi: 1750–1172–1-24 [pii]Google Scholar
  5. Girschick HJ, Seyberth HW, Huppertz HI (1999) Treatment of childhood hypophosphatasia with nonsteroidal antiinflammatory drugs. Bone 25 (5): 603–607CrossRefPubMedCentralGoogle Scholar
  6. Hofmann C, Girschick H, Mentrup B, Graser S, Seefried S, Liese J, Jakob F (2013a) Clinical aspects of hypophosphatasia: an update. Clin Rev Bone Miner Metab 11: 60–70. doi: 10.1007/s12018–013–9139–0
  7. Hofmann C, Girschick H, Mornet E, Schneider D, Jakob F, Mentrup B (2014) Unexpected high intrafamilial phenotypic variability observed in hypophosphatasia. Eur J Hum Genet. doi: 10.1038/ejhg.2014.10CrossRefPubMedCentralGoogle Scholar
  8. Hofmann C, Liese J, Schwarz T, Kunzmann S, Wirbelauer J, Nowak J, Hamann J, Girschick H, Graser S, Dietz K, Zeck S, Jakob F, Mentrup B (2013b) Compound heterozygosity of two functional null mutations in the ALPL gene associated with deleterious neurological outcome in an infant with hypophosphatasia. Bone 55 (1): 150–157. doi: S8756–3282(13)00089–6 [pii]Google Scholar
  9. Leung EC, Mhanni AA, Reed M, Whyte MP, Landy H, Greenberg CR (2013) Outcome of perinatal hypophosphatasia in Manitoba mennonites: A retrospective cohort analysis. JIMD Rep. doi: 10.1007/8904_2013_224Google Scholar
  10. Mornet E (2007) Hypophosphatasia. Orphanet J Rare Dis 2: 40CrossRefPubMedCentralGoogle Scholar
  11. Mornet E, Hofmann C, Bloch-Zupan A, Girschick H, Le Merrer M (2014) Clinical utility gene card for: hypophosphatasia - update 2013. Eur J Hum Genet 22 (4). doi: 10.1038/ejhg.2013.177
  12. Rathbun JC (1948) Hypophosphatasia; a new developmental anomaly. Am J Dis Child 75 (6): 822–831CrossRefPubMedCentralGoogle Scholar
  13. Rockman-Greenberg C (2013) Hypophosphatasia. Pediatric endocrinology reviews : PER 10 Suppl 2: 380–388Google Scholar
  14. Wenkert D, McAlister WH, Coburn SP, Zerega JA, Ryan LM, Ericson KL, Hersh JH, Mumm S, Whyte MP (2011) Hypophosphatasia: nonlethal disease despite skeletal presentation in utero (17 new cases and literature review). J Bone Miner Res 26 (10): 2389–2398. doi: 10.1002/jbmr.454CrossRefPubMedCentralGoogle Scholar
  15. Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, Van Sickle BJ, Simmons JH, Edgar TS, Bauer ML, Hamdan MA, Bishop N, Lutz RE, McGinn M, Craig S, Moore JN, Taylor JW, Cleveland RH, Cranley WR, Lim R, Thacher TD, Mayhew JE, Downs M, Millan JL, Skrinar AM, Crine P, Landy H (2012) Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 366 (10): 904–913. doi: 10.1056/NEJMoa1106173CrossRefPubMedCentralGoogle Scholar
  16. Whyte MP, Leung E, Wilcox W, Liese J, Reeves A, Melian A, Ordrljin T, Zhang H, Hofmann C (2014) Hypophosphatasia: A retrospective natural history study of the severe perinatal and infantile forms. Abstract Hypophosphatasia: A retrospective natural history study of the severe perinatal and infantile formsECTS 2014Google Scholar

Literatur zu Abschn. 6.4

  1. Hecht JT, Butler IJ (1990) Neurologic morbidity associated with achondroplasia. J Child Neurol 5: 84–97CrossRefPubMedCentralGoogle Scholar
  2. Spranger J, Langer LO, WiedemannH-R (1974) Achondroplasia; Bone dysplasias, An Atlas of Constitutional Disorders of Skeletal Development; Gustav Fischer Verlag, Stuttgart, S 55–61Google Scholar
  3. Stanley G, McLoughlin S, Beals RK (2002) Observations on the cause of bowlegs in achondroplasia. J Pediatr Orthop 22: 112–6PubMedPubMedCentralGoogle Scholar
  4. Zichner L (2003) Achondroplasie. Orthopädie und Orthopädische Chirurgie, Systemerkrankungen. Thieme Verlag, Stuttgart, S 17–28Google Scholar

Literatur zu Abschn. 6.5

  1. Masuyama M (1971) Thalidomide. Tokyo Univ Press, TokyoGoogle Scholar

Literatur zu Abschn. 6.6

  1. Bullough PG, Davidson DD, Lorenzo JC (1981) The morbid anatomy of the skeleton in osteogenesis imperfecta. Clin Orthop 159: 42–57Google Scholar
  2. Bundesverband Kleinwüchsige Menschen und ihre Familien e. V. Webseite des Bundesverbandes Kleinwüchsige Menschen und ihre Familien e.V.; . http://bkmf.de/letzter Zugriff 30.01.2015
  3. Burnei G, Vlad C, Georgescu I, Gavrilliu TS, Dan D (2008) Osteogenesis imperfecta: diagnosis and treatment. J Am Acad Orthop Surg 16: 356–366CrossRefPubMedCentralGoogle Scholar
  4. Cameron HU, Welsh RP (1988) Potential complications of total knee replacement following tibial osteotomy. Orthop Rev 17: 39–43Google Scholar
  5. Coe JD, Murphy WA, Whyte MP (1986) Management of femoral fractures and pseudofractures in adult hypophosphatasia. J Bone Joint Surg Am 68: 981–990CrossRefGoogle Scholar
  6. Eyres KS, Brown J, Douglas DL (1993) Osteotomy and intramedullary nailing for the correction of progressive deformity in vitamin D-resistant hypophosphataemic rickets. J R Coll Surg Edinb 38: 50–54Google Scholar
  7. Goldmann AB (1988) Osteogenesis imperfecta. In: Diagnosis of bone and joint disorders. Edited by Donald Resnick and Gen Niwayama. Ed. 2, , W.B. Saunders, Philadelphia, pp 3389–3400Google Scholar
  8. Goldmann AB, Davisdon D, Pavlov H, Bullough PG (1980) “Popcorn” calcifications: a prognostic sign in osteogenesis imperfecta. Radiology 136: 351–358CrossRefPubMedCentralGoogle Scholar
  9. Herzenberg JE, Paley D (1998) Leg lengthening in Children. Curr Opin Pediatr 10: 95–97CrossRefPubMedCentralGoogle Scholar
  10. Horton WA, Rotter JI, Rimoin DL, Scott CI, Hall JG (1978) Standard growth curvers for achondroplasia. J Pediatr 93: 435–438CrossRefPubMedCentralGoogle Scholar
  11. Kim RH, Scuderi GR, Dennis DA, Nakano SW (2011) Technical challenges of total knee arthroplasty in skeletal dysplasia. Clin Orthop Relat Res 469: 69–75CrossRefGoogle Scholar
  12. King JD, Bobechko WP (1971) Osteogenesis imperfecta. An orthopaedic description and surgical review. J Bone Joint Surg Am 53B: 72–85CrossRefGoogle Scholar
  13. Krishnan H, Patel NK, Skinner JA, Muirhead-Allwood SK, Briggs TW, Carrington RW, Miles J (2013) Primary and revision total hip arthroplasty in osteogenesis imperfecta. Hip Int 23: 303–309CrossRefPubMedCentralGoogle Scholar
  14. Lee ST, Song HR,Mahajan R, Makwana V, Suh SW, Lee SH (2007) Development of genu varum in achondroplasia: Relation to fibular overgrowth. J Bone Loint Surg Br 89: 57–61CrossRefGoogle Scholar
  15. Leung HW, Wong CW, Shen WY (2008) Intramedullary nailing for adult hypophosphatasia: a case report. J Orthop Surg (Hong Kong) 16: 385–388CrossRefPubMedCentralGoogle Scholar
  16. Muirhead-Allwood SK, Sandiford N, Skinner JA, Hua J, Kabir C, Walker PS (2010) Uncemented custom computer-assisted design and manufacture of hydroxyapatite-coated femoral components: survival at 10 to 17 years. J Bone Joint Surg Br 92: 1079–1084CrossRefGoogle Scholar
  17. Papagelopoulos PJ, Morrey BF (1993) Hip and knee replacement in osteogenesis imperfecta. J Bone Joint Surg Am 75: 572–580CrossRefGoogle Scholar
  18. Peretti G, Memeo A, Paronzini A, Marzorati S (1995) Staged lengthening in the prevention of dwarfism in achondroplastic children: a preliminary report. J Pediatr Orthop B 1995: 58–64CrossRefGoogle Scholar
  19. Petje G, Meizer R, Radler C, Aigner N, Grill F (2008) Deformity correction in children with hereditary hypophosphatemic rickets. Clin Orthop Relat Res 466: 3078–3085CrossRefPubMedCentralGoogle Scholar
  20. Platzer P, Thalhammer G, Vecsei V, Wozasek GE (2005) Surgical treatment of femoral bending deformity in a patient with vitamin D-resistant rickets. Wien Klin Wochenschr 117: 721–724CrossRefPubMedCentralGoogle Scholar
  21. Randle JA, Meisami-Fard B, McKee MD (1999) Mechanical failure of a gamma nail in a patient with an impending pathologic subtrochanteric fracture. Can J Surg 42: 384–386Google Scholar
  22. Root L (1984) The treatment of osteogenesis imperfecta. Orthop. Clin. North America 15: 775–790Google Scholar
  23. Rosenberg AG, Barden RM, Galante JO (1990) Cemented and ingrowth fixation of the Miller-Galante prosthesis. Clinical and roentgenographic comparsion after three- to six-year follow-up studies. Clin Orthop Relat Res 260: 71–79Google Scholar
  24. Sekundiak TD (2005) Total hip arthroplasty in patients with dwarfism. Orthopedics 28 (9 Suppl): 1075–1078Google Scholar
  25. Shirley ED, Ain MC (2009) Achondroplasia: manifestations and treatment. J Am Acad Orthop Surg 17: 231–241CrossRefPubMedCentralGoogle Scholar
  26. Song HR, Choonia AT, Hong SJ et al. (2006) Rotational profile oft the lower extremity in achondroplasia: Computed tomographic examination of 25 patients. Skeletal Radiol 35: 929–934CrossRefPubMedCentralGoogle Scholar
  27. Trivella GP, Brigadoi F, Aldegheri R (1996) Leg lengthening in Turner dwarfsim. J Bone Joint Surg (Br) 78: 290–293Google Scholar
  28. Windsor RE, Insall JN, Sculco TP (1986) Bone grafting of tibial defects in primary and revision total knee arthroplasty. Clin Orthop Relat Res 205: 132–137Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  • Uwe Martin Maus
    • 1
  • Thomas Vetter
    • 2
  • J. Oliver Semler
    • 3
  • Christine Hofmann
    • 4
  • Klaus M. Peters
    • 5
  • Andreas Roth
    • 6
  • André Sachse
    • 7
  1. 1.Universitätsklinik für Orthopädie und UnfallchirurgiePius-Hospital OldenburgOldenburgDeutschland
  2. 2.Orthopädie und UnfallchirurgieUniversitätsmedizin der Johannes Gutenberg-UniversitätMainzDeutschland
  3. 3.Klinik für Kinder- und JugendmedizinUniversitätsklinikum KölnKölnDeutschland
  4. 4.Kinderklinik der Bayerischen Julius-Maximilians- UniversitätUniversitätsklinikum WürzburgWürzburgDeutschland
  5. 5.Orthopädie und OsteologieDr. Becker Rhein-Sieg-KlinikNümbrechtDeutschland
  6. 6.Klinik für Orthopädie, Unfallchirurgie und Plastische ChirurgieUniversität LeipzigLeipzigDeutschland
  7. 7.Orthopädische Klinik am Waldkrankenhaus Rudolf-ElleFriedrich-Schiller-Universität JenaEisenbergDeutschland

Personalised recommendations